Andreessen Marc L's Form 4 filing
Braveheart Bio, Inc. (BRVE) · filed Aug 11, 2026
- Accession no.
- 0001231919-26-000859
- Filed
- Aug 11, 2026, 5:53 PM ET
- Trade date
- Aug 7, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $19.8M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Andreessen Marc LCIK 0001160077 | 10% Owner |
| Horowitz Benjamin ACIK 0001166586 | 10% Owner |
| AH Bio Fund IV, L.P.CIK 0001889476 | 10% Owner |
| AH Equity Partners Bio IV, L.L.C.CIK 0001889898 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | CConversionAcquired | +9,132,420 | –F1 | – | 9,132,420 | Indirect | |
| Aug 7, 2026 | Common Stock | PPurchaseAcquired | +1,100,000 | $18.00 | +$19,800,000 | 10,232,420 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | CConversionDisposed | −9,132,420 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 4.38-for-1 basis. The Series A Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.